Nebraska Cancer Specialists Named GO2 Center of Excellence for Lung Cancer Screening and Care
Nebraska Cancer Specialists (NCS) has been named a Center of Excellence (COE) by GO2 for Lung Cancer (GO2) in both Lung Cancer Screening and Lung Cancer Care, recognizing the organization’s commitment to delivering patient-centered, evidence-based services across the full lung cancer continuum. An estimated 237,000 Americans are diagnosed with lung cancer each year, and the disease remains the leading cause of cancer-related deaths in the U.S. Early detection through low-dose CT (LDCT) screening and advances in treatment are transforming outcomes, helping more people live longer, higher-quality lives.
“We are proud to have Nebraska Cancer Specialists join the national network of GO2 for Lung Cancer Centers of Excellence,” said Joelle Fathi, Chief Healthcare Delivery Officer at GO2 for Lung Cancer. “Most people at risk for or living with lung cancer receive care close to home. Through the GO2 COE network, we support collaboration and knowledge sharing that brings the latest advancements in early detection, treatment, and care directly to local communities.”
Excellence in Screening and Care
As a Center of Excellence in Lung Cancer Screening, NCS provides low-dose CT scans for high-risk individuals, following evidence-based guidelines from leading organizations such as the American College of Radiology (ACR) and the National Comprehensive Cancer Network (NCCN). The program emphasizes patient-centered communication, shared decision-making, and coordinated follow-up.
As a Center of Excellence in Lung Cancer Care, NCS demonstrates access to comprehensive cancer services, including medical, radiation, and surgical oncology. Care is guided by clinical best practices and delivered through a multidisciplinary, team-based approach to ensure patients receive personalized, coordinated treatment.
“At Nebraska Cancer Specialists, we are dedicated to providing the highest quality care at every stage,” said Danielle Geiger, MSN, APRN-NP, AOCNP, Chief Operating Officer. “From early detection through advanced treatment, this recognition reflects our commitment to responsible screening, leading-edge therapies, and compassionate support for people in our communities facing lung cancer.”